Redburn raised the price target for the Moderna Inc. (NASDAQ:MRNA) stock from ‘a Sell’ to ‘a Neutral’. The rating was released on February 01, 2023, according to finviz. The research report from BofA Securities has upgraded the stock from Underperform to Neutral, with a price target set at $180. The stock was initiated by UBS, who disclosed in a research note on January 21, 2023, to Neutral and set the price objective to $221. Sponsored
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Moderna Inc.
More Stories
The Clorox Company (CLX) Stock to return to profitability in the near future
Wells Fargo lowered the price target for the The Clorox Company (NYSE:CLX) stock to ‘an Underweight’. The rating was released on February
Startup Digest: PhonePe officially announces Smart Speaker, AWE Funds launches Rs 350 crore maiden India fund, Northern Arc Capital gets $25 million
Here are the top headlines from the startup space.
VTEX (NYSE:VTEX) Trading Up 10.9%
VTEX (NYSE:VTEX – Get Rating) was up 10.9% on Monday . The stock traded as high as $4.57 and last traded at $4.56. Approximately 7,550 shares traded hands during mid-day trading, a decline of 99% from…
Quanterix Corporation (QTRX) Stock is the one stock you should own forever
SVB Leerink lowered the price target for the Quanterix Corporation (NASDAQ:QTRX) stock from ‘an Outperform’ to ‘a Mkt performȁ
Is price-to-earnings ratio of 10.34 for Cenovus Energy Inc. (NYSE:CVE) Stock digestible?
Sponsored The latest trade, Performances and Moving Averages give us the following Picture The share price of Cenovus Energy Inc. (NYSE:CVE) raised 2.05% to close Friday’s market session at $16.43,…
Grupo Supervielle (NYSE:SUPV) and Oxford Bank (OTCMKTS:OXBC) Head to Head Review
Grupo Supervielle (NYSE:SUPV – Get Rating) and Oxford Bank (OTCMKTS:OXBC – Get Rating) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses…